Printer-friendly versionPrinter-friendly version
General Information
The date when the cluster organisation was established: 
Friday, 23 October, 1998
Number of staff in the management team of the cluster organisation : 
over 30
Île de France
Cluster Excellence Label: 
Bronze Label
Membership to other networks/partnerships: 
CEBR (Council of European BioRegions)
French Teach #HealthTech
EIH Health
France Cluster
Bio Innovation Organisation
AURP (Association of University Research Parks)
Cluster Management Team: 
ECCP Responsible Person
+33 (0) 1 60 87 44 68
Internationalisation Responsible
+33 (0) 1 60 87 83 15
Project Manager
+33 (0) 1 60 87 35 73
Project Manager
+ 33 (0) 1 60 87 35 13
Languages spoken: 
Sectoral and Industrial Focus
Sectoral Industries: 
Business Services
Technology fields: 
Synthetic Biology
Gene - DNA Therapy
S3 EU priority areas: 
Industrial biotechnology
Emerging industries: 
Creative Industries
Areas of specialisation of the cluster not covered above: 
Personalized medicine, biotherapies, genomedicine and genomics
Composition of the cluster
Total number of members: 
Number of SME members: 
Number of start-ups among SME members: 
Number of larger company members: 
Number of research organisations/universities/technology centres: 
Number of other ecosystem actors : 
Entrepreneurship and scale-up support facilities in the cluster's ecosystem (see "Organisation type"): 
Name and link of major players: 
Larger Company
Global Bioenergies
Centre National de Recherche en Génomique Humaine
Research Organisation
Research Organisation
New England Biolabs
Larger Company
Research Organisation
Université Evry, Paris-Saclay
Cluster Strategy

Founded in 1998, Genopole is the oldest and largest biocluster in France. It was launched thanks to  the impetus of local public authorities such as France’s muscular dystrophy association (i.e., AFM-Téléthon) and France’s Ministry of Higher Education and Research. The sponsors of Genopole are currently the governments of the Region Île-de-France and the Department of Essonne, the City of Évry, as well as France’s Ministry of Higher Education, Research & Innovation.

Genopole’s focus is genomics-driven R&D and innovation. Genopole aims to enable the emergence of innovations that will improve growth, health economy, citizens’ health and environment.


The biocluster was a pioneer in France’s government-led biotechnology thrust of the late 90’s and has since grown to become one of the leading European world-class biotech hotspots that attracts and networks from new raising biotech stars (start-ups) to dynamic established SMEs/companies, as well as a number of public research laboratories and higher education stakeholders from the local Université d’Évry Paris-Saclay and the Hospital Center of South Grand Paris (Centre Hospitalier Sud-Francilien). Today, by offering the environnement and insfrastructures for bioentrepreneurs, Genopole is a leading-edge cluster in human, animal and microbial genetics, as well as has outstanding expertise in the field of innovative biotherapies, personalized medicine and industrial biotechnologies.

Genopole’s biotechcampus has excellent location factors: it is located in the neighboring cities of Évry and Corbeil-Essonnes in the Department of Essonne. Genopole is 20km from Orly Airport and 70km from Charles-de-Gaulle Airport, easily reachable by highway. Genopole is also easily accessible from Paris by public transport from main Paris railtrain stations.

Genopole is also strategically located on the south side of “Grand Paris” allowing to strenghen local and regional, sectorial and cross-sectorial collaborations/opportunities with a very dynamic scientific and technological ecosystem, as the Department of Essonne hosts a number of reputed academic institutions (École Polytechnique, Supelec, Télécom SudParis, Institut Mines-Télécom Business School, Centre des matériaux de l’École des mines), well-renowned public research institutes and organizations (CEA, CNRS, Curie, Institut Gustave Roussy, Inra, Inserm, Inria, Onera), as well as state-of-the-art scientific infrastructures (Synchrotron Soleil, NeuroSpin, Teratec). Moreover, the Department of Essonne is one of the few French departments to develop on its territory a technology ranging from the incubation of a project to its industrial application. Two sectors of excellence stand out: biotechnologies and optics / ICT (so called Optics Valley)

Today, thanks to a committed cluster management over 20 years, Genopole at a glance represents a mature and fertile cluster organisation with more than 2,300 staff members which are employed on-site by the 87 companies, 17 public research labs, and 29 cutting -edge shared-access technology platforms and facilities for R&D located on site. This unique Life Science ecosystem, including an hospital, a centre for clinical and transnational research and an University has provided nourishing environnement particularly for over 190 start-ups which have been accredited by Genopole over the last two decades, and have been assisted though customised specialised R&D and business support services. During that period, over €649 million have been raised by Genopole’s portfolio companies, and seven companies have been already listed on public markets.


Genopole's missions:

Genopole’s overall mission is to support R&D in genomics and genetics and the grow of biotechnology SMEs that pursue health, environmental and agri-food applications.

Genopole is a not-for-profit organisation (with a permanent staff of 48 pers.) which is acting as general manager, advocate, promoter, catalyst, facilitator, coordinator, and sometimes financial sponsor of the biocluster member’s developments.

Genopole’s principal objectives are to:

  • Support and coordinate R&D efforts and innovation initiatives in genomics and post-genomics sciences and technology;
  • Promote the growth of French biotechnology markets through direct incubation and business  support services to start-ups and early-stage companies;
  • Provide cutting-edge shared-access technological platforms to the laboratories and companies that request them to conduct their researches;
  • Provide entrepreneurship training programmes, as well as reinforce targeted teaching programmes in close collaboration with the Université d’Evry Paris-Saclay and the Université Paris-Saclay;
  • Facilitate communications between the biocluster’s stakeholders by organizing scientific and networking events on site as well as by reaching out to the media and the general public at large to generate a better understanding of the positive impact of genomics; 
  • Participate in the societal debate on ethical issues related to the development of biotechnology and human genomic research.
Do you have a formalised strategy?: 
Do you have a specific strategy focus that addresses internationalisation ?: 
Support services provided: 
Access to the European Internal market
Internationalisation support (= Access to third countries markets)
Access to private funding (connecting to investors, seed-capital, venture-capital, crowd-funding, etc.)
Access to technology services
Promotion of activities (marketing/ visibility)
Details of support services: 

The cluster organisation has set up set out an integrated development strategy to promote R&D , entrepreneurship and economic growth and particularly supports small and medium-sized enterprises as well as entrepreneurs and founders-to-be in the field of biotechnology with a broad range of services which are structured in four different interrelated departments:

  • “Genopole Entreprises” department provides access to the SHAKER and the BOOSTER programmes, as well as coaching and support services to entrepreneurs. Genopole Entreprises also develops prospecting actions and support for implantations of mature and high-growth businesses on the biocluster.
  • “Genopole Research & Global Infrastructure” department manages the development of the 28 existing open-access technology platforms and infrastructures, promotes the launch of collaborative R&D projects and strengthens the research potential of the biocluster.
  • “Genopole Communication” department manages on-site networking activities, as well as general public communications and press relations.
  • “Genopole International” department is responsible for international affairs and for developing cluster-to-cluster partnerships.

Our support services: 

A-Services for accelerating biotech innovation & bioentrepreneuship

Genopole has recently reengineered and reenergized its bioentrepeneurship programme, as driver for the translation of ideas into success stories. For this, in 2017, it has been launched a multistep programme specifically tailored to the Biotech sector, to guide future bioTech entrepreneurs from idea to success , as follows:

Step 1-Shaker programme: Services provided by the Shaker are designed particularly for doctoral and postdoctoral students, engineers, who come up with original ideas and innovative projects, and relating to applications in healthcare, environment, agritech, foodtech. Specifically, the Shaker’s services are designed to design and validate business concept as well as to support proof-of-concept experimentation by future biotech entrepreneurs, by providing free access to a dedicated research laboratory, the “Lab Biotech”, as well as facilitating ad hoc connections with top-notch scientific and technical personnel drawn from the 2,500-strong ecosystem of innovation managers, research scientists and entrepreneurs established companies on the site.

Shaker services also include initial training in entrepreneurship as its clientele is generally unfamiliar with the intricacies of the business world. This training is structured in  a series of introductory courses on financing means for biotechnology, biotech-specific legal and regulatory obligations, and business communications. The Shaker can also provide access to premarketing studies and other relevant information required to provide future biotech entrepreneurs a better idea of the road to come. The Shaker’s programme is for a period of six months that can be extended for another 6 months.

Step 2-Booster programme  : The Booster is the logical second step in Genopole’s offer to biotech entrepreneurs. This one-year program targets entrepreneurs whose companies (less than 2 years old) are considered to have high growth potential, either nationally or internationally, or both. Following a thorough diagnosis to establish a support plan that is specifically tailored for each company, the Booster services include 20 days of intensive training, coaching and mentoring, including assistance in developing  a bunises model and writing a strong business plan, in accelerating business development (including also co-financing consultancy mandates), as well as direct support in fund raising. The Booster programme also provides access to office and lab spaces, state-of-the-art technology platforms and contacts with experienced mentors.  The Booster’s programme duration  is of one year that can be extended for another 12 months.

To complement the Genopole’s all-round service package for bioentrepreneurs, the Growth Hub aims at supporting the mature start-ups to grow further into established SMEs, and eventually into small-caps. Based on the above mentioned services in any stage of the business service, Genopole is now recognized at regional, national and European as a key bioentrepeneurial ecosystem for accelerating biotech innovation.

B -Services for attracting biotech-SMEs and international biotech companies

One fo the key priorities of the economic and scientifc  growth strategy of the biocluster is to support the development of its park of mature biotech companies. For this, thanks to the business development team  of  the Genopole Entreprises department,  Genopole is carrying out a dedicated service to fluidify the cluster integration path, providing all the necessary  information needed (legal, scientific and technical partnerships, regulatory affairs, market access, public and private financing) by the interested company for its allocation .

The original proposal of Genopole is precisely to offer national and foreign companies a real operational follow-up during the implementation phase, from the identification phase to the installation phase, but also to offer support for the development of the company once set-up at Genopole.

C-Services for strenghening R&D potentiel and attracting talents

Genopole’s services is also to support fast-expanding R&D programmes, mainly on 1) genomic medicine, 2) stem cells and biotherapies and 3) synthetic and systems biology. In this perspective, Genopole set-up three different tools:

  1.  Genopole is funding or co-funding the acquisition of cutting-edge technologies, by launching an annual call for the provision of shared equipment for promising scientific or industrial projects.
  2. Genopole fosters emergence of new scientific leaders by offering a financial provision  to tenured researchers to create a team within already-established research units in the biocluster.  These grants, called ATIGES (French acronym for Actions Thématiques Incitatives de Genopole, or  Genopole’s Thematic Incentive Actions grants), are intended for researchers who already have a position within a public research organisation or who are likely to obtain such a position before the attribution of ATIGES grants. The themes of candidate projects must be coherent with Genopole’s centers of interest (e.g.,genomics and post-genomics, biotherapies, bioinformatics, biophysics, engineering sciences, as applied to large-scale biological domains such as transcriptomics, proteomics, metabolomics, systems biology, synthetic biology).
  3. Genopole promotes the “reverse brain drain”action. The purpose of Genopole’s postdoctoral repatriation allocations is to encourage and facilitate the return to France of French-educated Ph.D.s who are completing postdoctoral fellowships abroad. The program targets young research scientists with proven excellence in their field, and provides 2-year allocations to support the development of a research project to be conducted inside a laboratory or a company established in Genopole.

D-Services for answering to real estate needs

Genopole provides concrete solutions to real estate needs of already-established or future bioentrepeneurs by offering:

  • Offices that can be made available free of charge for defined periods of time to creators of companies.
  • An ISO 9001:2000-certified incubator fitted for early-stage biotechnology developments,  with fully-equipped offices, BSL1/2 labs ranging from 9 to 100 m2, as well as building services.
  • Mixed or tertiary facilities of offices and BSL1/2 laboratories that are modular and expandable, with shared-access equipment and services, ranging from 10 to 150 m2.
  • Fully-furnished mixed or tertiary facilities, ranging from 150 to 2,500 m2, for clients to launch their operations rapidly and control their set-up costs.
  • Unfurnished customizable floor space, ranging from 400 to 2,700 m2.
  • Land properties for companies and R&D centers in biotechnology;

Genopole’s four campuses in Évry currently cover 111,000 m2 (1,185,000 ft2) of offices and laboratory spaces, with the opening of a fifth campus planned for 2019. A residential tower for visitors and short-term residents, as well as a day nursery, were opened in early 2019. Additional 37,000 m2 (400,000 ft2) are under construction, or planned to open before 2021. The biocluster also offers a 700-seat conference facility.


Cooperation Activities
International Cooperation
The main countries targeted by the cluster organisation: 
United States
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Trans-national Cooperation
The main countries targeted by the cluster organisation: 
Our cluster organisation undertook the following trans-national activities to support our members: 
Participation at missions/events/study visits/fairs
Please explain: 

Genopole aims to advance close collaboration not only at Regional and National levels but also on an international level : it is internationaly minded. Thius,It has been established different cooperation agreements with foreign bioclusters and R&D parks, as well as in engaging in international activities, with a view to:

  1. Conducting reciprocal soft landing operations for companies from Genopole and international bioclusters seeking commercial developments in France and in Europe.
  2. Entering into international technology transfer projects.
  3. Developing R&D initiatives of common interest to parties.
  4. Completing benchmarking on current trends in foreign bioclusters and exchanging on best practices.

Genopole also participates actively in leading international biotech conferences and fairs, organizes missions abroad, hosts foreign delegations visits, and conducts benchmarking studies on existing bioclusters.

This continued partnership action involves the mutual exchange of information about new technologies on site, industrial development and academic opportunities as well as discussions on best practices in technology transfer and the support of small and medium-sized enterprises in the biotechnology sector. This has also paved the way for fruitful B2B working relationships between companies as well as companies and academic institutes, respectively.

In this context of Trans-national Cooperation policy,  in 2017, Genopole has been selected by the French Government to benefit from the “French Tech Visa program” developed for international companies and start-ups ( wishing to establish activities in France. The “French Tech Visa” is a simplified fast-track procedure to attract three types of international tech talent to deliver a residence permit (known as the "Passeport Talent", or Talent Passport).

Key 2017 facts :

  • 14 Foreign delegation visits  representing South Korea, Senegal, China, Québec, the Netherlands, Belgium, Japan and the United States
  • 6 Foreign delegation visits  representing South Korea, Senegal, China, Québec, the Netherlands, Belgium, Japan and the United States. Among them, the American company Illumina (world-leader in high throughput sequenat) in the biocluster chose Genopole for its arrival in continental Europe.
  • 115 M in export sales for accredited companies (2017 estimate)
  • Genopole was elected as a member of the administrative council and as co-president of the international committee of the Association of University Research Parks (AURP)
  • Genopole participated in the creation of the 2017 roadmap for French Tech #HealthTech, a thematic network connecting 24 French ecosystems for health sciences (medtech, eHealth, therapeutic biotech, silver economy, etc.). Created as part of the French Tech initiative of the French Ministry for the Economy, #HealthTech counts among its objectives, the creation of an international event to stimulate capital development investments in #HealthTech start-ups.
  • Genopole signed a cooperation agreement with the Néomed Institute in Montreal. Genopole's ties to Québec and Canada—a priority in its international deployment strategy—were further strengthened by the visits of two delegations from Génome Québec, an organism dedicated to genomics research.
Which clusters do you collaborate with?: 
Genome Quebec (Canada)
Biocat (Spain)
Shenzen (Chine)
BioPMed (Italy)
Cluster E-R (Italy)
GIS (Singapour)
BioM (Germany)
Hudson Alpha (USA)
Research Triangle Park ( USA)
HKSTP (Hong Kong)
IPark (Japon)
District 3 ( Canada)
Campania BioScience (Italy)
Rehovot (Israël)
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject NameLinkName & Description (Regional/National)

GEN.ERA* - Start in May 2020

*GEN.ERA : diGital gENomic Alliance to Explore new maRket for Acceleration

The GEN.ERA project, coordinated by Genopole®, is funded by the European Commission in the framework of the "Cluster Go International" call for tenders of the COSME programme.

It aims to strengthen the internationalization of genomics companies beyond Europe, through cooperation between clusters. For Genopole, the project marks an important step in its internationalisation strategy of. It also lays the foundations for European collaboration in genomics.

It brings together clusters from Italy (Distretto Tecnologico Campania Bioscience), Estonia (Tartu BT Park), Finland (Turku Science Park Ltd) and the East-Netherlands Development Agency. The aim is to build in two years a European inter-cluster strategy to identify promising markets and facilitate their access to companies positioned in the genomics value chain.

By sharing their expertise and building a common internationalisation strategy, the five partners will be able to approach the global market as a single large European cluster and thus support the development of their companies, start-ups and SMEs outside Europe. The project will start at the beginning of May; companies will be invited to participate in the implementation of this ambitious project.

Open to EU opportunities. Please contact our European project manager team.

Success Story / Achievements: 

Key recent facts

  • 2018: Genopole was awarded the Bronze Label by the European Secretariat for Cluster Analysis (ESCA) as a result of the analyses by the experts who were accredited in the European Union and France and examined the activities, structures and governance of more than 350 clusters across Europe. The label is awarded after a thorough assessment of various aspects including the cluster’s structure, management and governance, strategy, financing, services offered, connections, intra-cluster interaction, achievements and recognition.
  • 2017 : the estimated sales reported by Genopole companies increased appreciably in 2017, cumulatively attaining €214 M (compared to €208 M in 2016). The number of companies achieving sales has increased constantly over the past four years.
  • 2017 : €623 Million raised by companies : the cumulative total of financing raised by Genopole-accredited companies since 1998 passed the €600 M threshold, growing from €579 M in 2016 to €623 M in 2017.

Some recent business successes:

  • Global Bioenergies raised €10.25 M in a private placement with qualified French and international investors
  • Endodiag, a specialist in the development of endometriosis diagnostics, raised €4 M from CM-CIC Innovation (primary contributor) and BNP Paribas Développement, money earmarked for the clinical validation and commercial preparation of its product EndoDtect.

Keep updated about Genopole :  (in French)

Have a look at your 2018 Annual Report : (interactive version in French and in English)

Why should partners choose you for cooperation?: 
  • Founded in 1998, Genopole can provide a 20-years of knowledge and expertise in Life sciences and more particularly in genomics biotherapies, synthetic biology and entrepreneurship.
  • An innovation and business ecosystem with more than 2,300 staff members which are employed by 96 companies, 17 public research labs, and 28 cutting-edge shared-access technology platforms and facilities for R&D.
  • A mature and fertile biotech ecosystem with innovative companies and over 200 start-ups which have been accredited by Genopole over the last two decades, and have been assisted though customised specialised R&D and business support services. During that period, over €649 million have been raised by Genopole’s portfolio companies, and seven companies have been already listed on public markets.
  • An integrated cluster organisation to promote R&D, entrepreneurship and economic growth and particularly to support small and medium-sized enterprises as well as entrepreneurs and founders-to-be in the field of biotechnology with a dedicated staff providing access to the SHAKER (Incubator) and the BOOSTER (Accelerator) programmes, as well as coaching and support services to entrepreneurs. Genopole also develops prospecting actions and support for implantations of mature and high-growth businesses on the biocluster.
  • A broad range of services for (1) accelerating biotech innovation & bioentrepreneurship, (2) attracting biotech-SMEs and international biotech companies, (3) strenghtening R&D potential and attracting talents and (4) answering to real estate needs.
  • A dynamic and intense cluster life with scientific and industrial events and networking activities with international, European, national and regional bioclusters, technology centres and other scaling-up support organisations.